{"slideshow_credits": null, "snippet": "Shire\u2019s board still has some leverage. For one, there\u2019s AbbVie\u2019s own weakness, because roughly 58 percent of its sales come from one drug, Neil Unmack and Robert Cyran of Reuters Breakingviews write.", "abstract": "Shire\u2019s board still has some leverage. For one, there\u2019s AbbVie\u2019s own weakness, because roughly 58 percent of its sales come from one drug, Neil Unmack and Robert Cyran of Reuters Breakingviews write.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Neil", "role": "reported", "lastname": "UNMACK", "rank": 1, "organization": ""}, {"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 2, "organization": ""}], "original": "By NEIL UNMACK and ROBERT CYRAN"}, "web_url": "http://dealbook.nytimes.com/2014/07/08/shire-can-get-higher-bid-from-abbvie/", "lead_paragraph": null, "headline": {"main": "Shire Can Get Higher Bid From AbbVie", "kicker": "DealBook"}, "_id": "53bc408938f0d846b5b5d152", "word_count": "369", "multimedia": [], "pub_date": "2014-07-08T15:02:08Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "AbbVie Inc", "rank": "1"}, {"name": "organizations", "value": "Shire PLC", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}